Jaguar Health announced the activation of the investigational new drug (IND) application filed by its subsidiary
@NapoPharma
for use of Napo’s plant-based medicine for prophylaxis & symptomatic relief of cancer therapy-related diarrhea
#PlantBasedMedicines
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
#JAGX
Jaguar Health today announced that it has established a new Investigational New Animal Drug file with the Center for Veterinary Medicine of the U.S. Food and Drug Administration for crofelemer to treat general, non-infectious diarrhea in dogs.
Jaguar Health Announces Submission of Clinical Trial Applications for the Rare Disease Indications Microvillus Inclusion Disease and Short Bowel Syndrome in Europe
#JAGX
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
#JAGX
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
#JAGX
Save the date: On August 13 at 8:30 am ET Jaguar Health will host an investor call to review second-quarter 2020 financials and business updates for $JAGX. Get details here:
#PlantBasedMedicines
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Today on
#WorldAIDSDay
, we reflect on the worldwide response to the HIV/AIDS epidemic, while also remembering those we've lost. This year’s theme of “Resilience and Impact” is more important than ever & we are proud to be part of such an inspiring community.
#PlantBasedMedicines
Jaguar Health to present January 31 at The Microcap Conference and participate in a fireside chat February 1 at the Lytham Partners Investor Select Conference
Jaguar today announced that it has reached agreement with the FDA on the design and conduct of a clinical field study of Canalevia-CA1, the company's FDA conditionally approved prescription drug for dogs, for full approval of the product.
Jaguar Health today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi to Direct Relief, a Santa Barbara, California-based humanitarian aid organization.
For
#InternationalJaguarDay
, we take a moment to pay homage to the beautiful symbolism, cultural connection & heritage of the Jaguar. Read more from Dr. Steven King, our Chief Sustainable Supply, Ethnobotanical Research & IP Officer:
Photos: Chris Scharf
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
#JAGX
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
#crofelemer
Study by Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
#JAGX
Today we announced the
@FDA
invited Jaguar Health to expedite submission of regulatory filing for approval of our drug candidate to treat chemotherapy-induced diarrhea in dogs. Read more here:
#PlantBasedMedicines
We have submitted to the
@US_FDA
’s Center for Veterinary Medicine the last required technical section to support approval of Jaguar's oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs. Read more:
#PlantBasedMedicines
.
@napopharma
's monthly “HIV Community Conversations” series brings key advocates & activists in the HIV community together to talk about the issues that matter most to people living with & affected by HIV/AIDS. More:
#JAGX
$JAGX
Two Investigator-Initiated Responder Analysis Trials of Jaguar's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
#JAGX
Napo’s FB live series “HIV Community Conversations presented by
@napopharma
” brings key advocates and activists in the
#HIV
community together to talk about the issues that matter most to people living with and affected by HIV/AIDS.
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials. REMINDER: Jaguar to host investor webcast Monday, August 22nd at 8:30 a.m. Eastern regarding second quarter 2022 financials and company updates.
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome & Congenital Diarrheal Disorders
#JAGX
Jaguar to hold investor webcast January 12th at 10:30 AM EST to highlight unmet medical need of cancer therapy-related diarrhea and Jaguar's mental health Entheogen Therapeutics Initiative to discover novel therapies derived from psychoactive plants
Jaguar announces completion of key milestone in process of establishing Indena as an approved crofelemer manufacturer, supporting expansion of manufacturing volume required for potential additional indications for crofelemer, including CTD
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
As friends of the environment and local and Indigenous communities, we stand behind the fight to protect our planet,
#IndigenousRights
and support Nemonte Nenquimo, one of
@TIME
’s 100 most influential people in the world. Read her inspiring story:
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
#JAGX
Jaguar Health and Filament Health, with funding from One Small Planet, form joint venture Magdalena Biosciences to develop botanical pharmaceutical drug candidates for mental health illnesses
Napo Pharmaceuticals, a Jaguar family company, announced that a new US patent has been issued to Napo for methods for treating congenital diarrheal disorders with crofelemer, Napo's novel plant-based prescription drug.
#JAGX
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar’s Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
"Forests provide materials for food, medicine, shelter, income, and forests provide habitat for millions of species of plants, animals, birds, insects and microorganisms" ~ Ethnobotanist Dr. Steven King Learn more:
#IntlForestDay
🌲🌳🌴🌎
Jaguar CEO Lisa Conte was interviewed recently by Pharmaceutical Executive to discuss how a climb up Mount Kilimanjaro would spark a decades-long quest to accelerate breakthroughs in plant-based drugs and supportive care.
Jaguar is pleased to announce that Sandra M. Swain, MD, FACP, FASCO, an internationally renowned physician/scientist with 30+ years of experience, has joined our Scientific Advisory Board.
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
#crofelemer
We're excited to announce that our subsidiary
@NapoPharma
launched a web-based iAssist component of the NapoCares patient support program to automate the patient prescription process for Mytesi® (Crofelemer):
#PlantBasedMedicines
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8, 2023 from 1:00 PM to 2:30 PM EST
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
#JAGX
#Crofelemer
We are happy to share some exciting news in the rare disease space - an independent study demonstrates the potential of our drug crofelemer to treat microvillus inclusion disease (MVID).
REMINDER: Jaguar to Hold Investor Webcast Thursday, Jan 12th at 10:30 AM EST to Highlight Unmet Medical Need of CTD and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
“We believe his broad sales, marketing, and analytical expertise in the pharmaceutical industry, and in the HIV sector at
@napopharma
, will play a significant role as we continue to focus on expanding sales of our Mytesi drug product..." More:
#JAGX
$JAGX
Jaguar Health today announced that on Tuesday, January 31, 2023 Lisa Conte, Jaguar's president, founder, and CEO, will present at the virtual Lytham Partners Investor Select Conference.
Preclinical Study Results Expected to Provide Key Supportive Data for Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Targeted Cancer Therapy. More:
#JAGX
$JAGX
An article titled “Jaguar Health seeks pharma partner for plant-based cancer supportive care drug, CEO says” was published October 18, 2023 in Mergermarket.
#jagx
#crofelemer
Study data on quality of life for breast cancer patients and survivors, supported by Napo Pharmaceuticals (a Jaguar Health family company), published on San Antonio Breast Cancer Symposium (SABCS) website
#sabcs2023
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials. REMINDER: Jaguar to host investor webcast Monday, November 14th at 8:30 a.m. Eastern regarding third quarter 2022 financials and company updates.
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million. Jaguar to host investor webcast Monday, March 27th at 8:00 a.m. Eastern regarding 2022 financials and company updates.
#JAGX
#Crofelemer
Today is National Latinx AIDS Awareness Day. Visit
@HIVGov
for information about
#HIV
testing, prevention and awareness in Latinx and Hispanic communities:
#NLAAD2020
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
#Canalevia
Lisa Conte, Jaguar's president, founder, and CEO, will be presenting at
#NobleCon18
at the Hard Rock / Guitar Hotel on Thursday, April 21, 2022. Admission is free for investors at any level – institutional through to self-directed novices. Register at